UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma

Sibirskiĭ onkologicheskiĭ zhurnal, 2023-02, Vol.22 (1), p.5-14

2023

Volltextzugriff (PDF)

The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2022-11, Vol.24 (3), p.340-344

2022

Volltextzugriff (PDF)

Analysis of frequency ofgenotypes and alleles of rs2227983 polymorphism of EGFR gene among patients with allergic bronchial asthma with various levels of control

Tuberkulëz i bolezni lëgkikh, 2022-06, Vol.100 (5), p.48-54

2022

Volltextzugriff (PDF)

Impact of preoperative targeted therapy duration on survival in patients with distant primary site and Stage III-IV non-small cell lung cancer in the presence of mutations in the EGFR gene

Onkologii͡a︡ (Moscow, Russia : 2012), 2022, Vol.11 (1), p.28

2022

Volltextzugriff (PDF)

THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE

Sibirskiĭ onkologicheskiĭ zhurnal, 2021-10, Vol.20 (5), p.149-161

2021

Volltextzugriff (PDF)

Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation

Medicinskij sovet, 2021-08 (9), p.42-47

2021

Volltextzugriff (PDF)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

Medicinskij sovet, 2019-06 (10), p.110-114

2019

Volltextzugriff (PDF)

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice

Uspehi molekulârnoj onkologii, 2018-11, Vol.5 (3), p.17-24

2018

Volltextzugriff (PDF)

Role of surgical treatment in patients with EGFR mutation-positive locally advanced and disseminated non-small-cell lung cancer

Onkologii͡a︡ (Moscow, Russia : 2012), 2021, Vol.10 (6), p.56

2021

Volltextzugriff (PDF)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS

Sibirskiĭ onkologicheskiĭ zhurnal, 2020-12, Vol.19 (6), p.119-125

2020

Volltextzugriff (PDF)

The role of polymorphism of the epidermal growth factor gene in the formation of severe manifestations of skin toxicity caused by the use of EGFR inhibitors

Rossiĭskiĭ zhurnal kozhnykh i venericheskikh boleznei, 2023-11, Vol.26 (5), p.431-439

2023

Volltextzugriff (PDF)

Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation

Medical Council, 2018-11 (19), p.130-135

2018

Volltextzugriff (PDF)

Osimertinib and routine practice: the experience of the drug application in different clinical situations in case of metastatic non-small cell lung cancer with an EGFR mutation. Case report

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2022-04, Vol.24 (1), p.41-49

2022

Volltextzugriff (PDF)

METASTATIC COLORECTAL CANCER MCRC WITH WILD-TYPE RAS: THE CONTINUATION OF ANTI-EGFR THERAPY WITH A CHANGE OF CHEMOTHERAPY AFTER DISEASE PROGRESSION

Voprosy onkologij, 2017-03, Vol.63 (3), p.456-460

2017

Volltextzugriff (PDF)

The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2018-09, Vol.20 (3), p.10-18

2018

Volltextzugriff (PDF)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Medicinskij sovet, 2020-12 (20), p.194-198

2020

Volltextzugriff (PDF)

TECHNICAL ASPECTS OF LIQUID BIOPSY: INFLUENCE OF PREANALYTICAL PARAMETERS ON THE CONCENTRATION OF CIRCULATING TUMOR DNA IN PLASMA OF CANCER PATIENTS

Voprosy onkologij, 2020-04, Vol.66 (4), p.391-397

2020

Volltextzugriff (PDF)

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy

Medicinskij sovet, 2020-07 (9), p.182-189

2020

Volltextzugriff (PDF)

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES

Medicinskij sovet, 2017-11 (14), p.46-55

2017

Volltextzugriff (PDF)

PROGNOSTIC VALUE OF PET/CT WITH 18F-FDG FOR EGFR GENE MUTATIONS STATUS EVALUATION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Russian Electronic Journal of Radiology, 2020, Vol.10 (1), p.191-205

2020

Volltextzugriff (PDF)

Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma

Medicinskij sovet, 2019-06 (10), p.142-145

2019

Volltextzugriff (PDF)

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2018-06, Vol.20 (2), p.50-54

2018

Volltextzugriff (PDF)

A study of immunohistochemical markers in the epidermis and dermis to measure the effect of topical preparations on the regeneration of skin

Klinicheskai͡a︡ dermatologii͡a︡ i venerologii͡a, 2019, Vol.18 (4), p.460

2019

Volltextzugriff (PDF)

Therapy for patients with non-small cell lung cancer in the Russian Federation: EPICLIN-Lung study

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2016-12, Vol.18 (4), p.27-33

2016

Volltextzugriff (PDF)

THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

Medical Council, 2016-12 (10), p.66-72

2016

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

SpracheRussisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(6)

Publikationsform

Artikel
(30)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

IngentaConnect Journals
(8)
IngentaConnect
(8)
EZB-FREE-00999 freely available EZB journals
(6)
MEDLINE
(1)

Menü

Weitere Dienste

Einstellungen

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma

The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis

Analysis of frequency ofgenotypes and alleles of rs2227983 polymorphism of EGFR gene among patients with allergic bronchial asthma with various levels of control

Impact of preoperative targeted therapy duration on survival in patients with distant primary site and Stage III-IV non-small cell lung cancer in the presence of mutations in the EGFR gene

THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE

Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice

Role of surgical treatment in patients with EGFR mutation-positive locally advanced and disseminated non-small-cell lung cancer

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS

The role of polymorphism of the epidermal growth factor gene in the formation of severe manifestations of skin toxicity caused by the use of EGFR inhibitors

Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation

Osimertinib and routine practice: the experience of the drug application in different clinical situations in case of metastatic non-small cell lung cancer with an EGFR mutation. Case report

METASTATIC COLORECTAL CANCER MCRC WITH WILD-TYPE RAS: THE CONTINUATION OF ANTI-EGFR THERAPY WITH A CHANGE OF CHEMOTHERAPY AFTER DISEASE PROGRESSION

The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

TECHNICAL ASPECTS OF LIQUID BIOPSY: INFLUENCE OF PREANALYTICAL PARAMETERS ON THE CONCENTRATION OF CIRCULATING TUMOR DNA IN PLASMA OF CANCER PATIENTS

Study of EGFR expression in tumor tissue in patients with locally advanced oral cavity cancer receiving cetuximab therapy

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES

PROGNOSTIC VALUE OF PET/CT WITH 18F-FDG FOR EGFR GENE MUTATIONS STATUS EVALUATION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

A study of immunohistochemical markers in the epidermis and dermis to measure the effect of topical preparations on the regeneration of skin

Therapy for patients with non-small cell lung cancer in the Russian Federation: EPICLIN-Lung study

THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

Aktive Filter

Suchergebnisse filtern